Department of Pharmacology, JSS College of Pharmacy (Jagadguru Sri Shivarathreeshwara University), Rocklands, Udhagamandalam, Tamil Nadu, 643001, India.
Naunyn Schmiedebergs Arch Pharmacol. 2018 May;391(5):463-479. doi: 10.1007/s00210-018-1479-3. Epub 2018 Feb 23.
Breast cancers contain small population of tumor-initiating cells called breast cancer stem cells (BCSCs), which are spared even after chemotherapy. Recently, BCSCs are implicated to be a cause of metastasis, tumor relapse, and therapy resistance in breast cancer. BCSCs have unique molecular mechanisms, which can be targeted to eliminate them. These include surface biomarkers, proteins involved in self-renewal pathways, drug efflux transporters, apoptotic/antiapoptotic proteins, autophagy, metabolism, and microenvironment regulation. The complex molecular mechanisms behind the survival of BCSCs and pharmacological targets for elimination of BCSCs are described in this review.
乳腺癌中存在一小群被称为乳腺癌干细胞 (BCSCs) 的肿瘤起始细胞,即使在化疗后这些细胞也能幸免。最近,BCSCs 被认为是乳腺癌转移、肿瘤复发和治疗耐药的原因。BCSCs 具有独特的分子机制,可以针对这些机制来消灭它们。这些机制包括表面生物标志物、参与自我更新途径的蛋白质、药物外排转运蛋白、凋亡/抗凋亡蛋白、自噬、代谢和微环境调节。本综述描述了 BCSCs 存活背后的复杂分子机制和消除 BCSCs 的药理学靶点。